Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to REPL. [ FAQ on what and how to ask] For non-REPL questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, United States, 01801
Employees: 465
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
CEO & Director
Chief Financial Officer
Chief Medical Officer
Executive Chairman
Senior Vice President of Quality Assurance
Senior Vice President of Regulatory Affairs
Chief Commercial Officer
My Watchlist
